Welcome to our dedicated page for Tango Therapeutics news (Ticker: TNGX), a resource for investors and traders seeking the latest updates and insights on Tango Therapeutics stock.
Tango Therapeutics, Inc. (NASDAQ: TNGX) is a clinical-stage biotechnology company focused on precision cancer medicines, and its news flow reflects ongoing progress in oncology research, clinical development, and corporate strategy. The company describes itself as dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer, using the genetic principle of synthetic lethality to identify and pursue critical targets in tumors.
News about Tango Therapeutics often highlights updates from its clinical pipeline, including vopimetostat (TNG462), an oral MTA-cooperative PRMT5 inhibitor for MTAP-deleted cancers, TNG456, a brain-penetrant PRMT5 inhibitor in development for glioblastoma and malignant glioma, and TNG260, a first-in-class CoREST complex inhibitor being evaluated with pembrolizumab in STK11-mutant solid tumors. Press releases have detailed Phase 1/2 clinical data, trial enrollment status, and regulatory designations such as Orphan Drug Designation for TNG456.
The company also issues news on corporate and financial developments, including leadership transitions, board appointments, equity financings, and at-the-market offering agreements documented in SEC filings. Announcements about participation in major healthcare investment conferences and scientific meetings, such as the J.P. Morgan Healthcare Conference and the Society for Immunotherapy of Cancer (SITC) Annual Meeting, provide additional context on how Tango Therapeutics communicates its strategy and data to investors and the scientific community.
Investors and followers of TNGX can use this news page to review company-issued press releases on clinical results, pipeline milestones, financing transactions, and governance changes, offering a consolidated view of how Tango Therapeutics is advancing its precision oncology programs based on synthetic lethality and targeted cancer biology.
Tango Therapeutics (NASDAQ: TNGX), a clinical-stage biotechnology company focused on precision cancer medicines, has announced its participation in three major investment bank conferences in early 2025.
The company will participate in:
- The B Riley Precision Oncology & Radiopharma Conference in New York, featuring a panel discussion on 'Pushing Tumors Over the Edge with Synthetic Lethality' on February 28 at 9:00 AM ET
- The Leerink Global Healthcare Conference in Miami, hosting a fireside chat on March 12 at 2:20 PM ET
- The Barclays 27th Annual Global Healthcare Conference in Miami on March 13, available for one-on-one meetings
Webcasts will be available on the company's website under the 'Events & Presentations' tab, with replays archived for 90 days post-presentation.
Tango Therapeutics (NASDAQ: TNGX), a clinical-stage biotechnology company focused on precision cancer medicines, has announced its participation in the upcoming Guggenheim SMID Cap Biotechnology Conference. Barbara Weber, M.D., the company's President and CEO, will engage in a fireside chat scheduled for Wednesday, February 5, 2025, at 10:00 AM ET.
The event will be accessible through a live webcast, available at the provided link and through the company's website under the 'Events & Presentations' section of the Investors page. The presentation recording will remain available on Tango's website for 90 days following the event.
Tango Therapeutics (NASDAQ: TNGX) announced that its Compensation Committee granted equity awards to a new employee under its 2023 Inducement Plan. The grants include a non-qualified stock option to purchase 187,500 shares at $3.89 per share and 31,250 restricted stock units (RSUs). The stock options will vest 25% on November 18, 2025, with remaining shares vesting monthly over 36 months. The RSUs will vest in three tranches: 10,416 shares in 2025, 10,417 shares in 2026, and 10,417 shares in 2027, subject to continued employment.
Tango Therapeutics (NASDAQ: TNGX), a clinical-stage biotechnology company focused on precision cancer medicines, announced that their President of Research & Development, Adam Crystal, M.D., Ph.D., will present at the Piper Sandler 36th Annual Healthcare Conference. The presentation is scheduled for Thursday, December 5, 2024, at 1:30 PM ET. A live webcast will be available on the company's website under the 'Events & Presentations' section, with a replay accessible for 90 days after the event.
Tango Therapeutics (NASDAQ: TNGX) reported Q3 2024 financial results and business updates. The company highlighted positive clinical activity for TNG462 across multiple tumor types, including a 43% ORR in cholangiocarcinoma. A new clinical collaboration with Revolution Medicines was established to evaluate TNG462 combinations. The company reported $293.3 million in cash, with runway into Q3 2026. Q3 2024 financial results showed collaboration revenue of $11.6 million and a net loss of $29.2 million ($0.27 per share). R&D expenses increased to $33.3 million, up from $27.1 million in Q3 2023.
Tango Therapeutics announced positive updates on its PRMT5 program. TNG462 showed promising clinical activity in multiple tumor types, including NSCLC and pancreatic cancer, with patients maintaining treatment for a median of 24 weeks. The company will advance TNG462 into full development and plans multiple combination studies in 1H 2025. While discontinuing TNG908 enrollment due to insufficient CNS exposure in glioblastoma, Tango is introducing TNG456, a next-generation brain-penetrant PRMT5 inhibitor with enhanced potency, set to enter clinical trials in 1H 2025. A clinical collaboration with Revolution Medicines was established to evaluate TNG462 in combination with RAS(ON) inhibitors.
Tango Therapeutics (NASDAQ: TNGX), a clinical-stage biotechnology company focused on precision cancer medicines, has announced its participation in two upcoming investor conferences. Barbara Weber, M.D., President and CEO of Tango Therapeutics, will represent the company at these events:
1. 2024 Wells Fargo Healthcare Conference on September 4, 2024, at 12:45 PM ET in Boston, MA.
2. 2024 Cantor Global Healthcare Conference on September 17, 2024, at 9:10 AM ET in New York, NY.
Live webcasts of the presentations will be available on the company's website under the 'Events & Presentations' tab on the 'Investors' page. Replays will be archived for 90 days following each presentation.
Tango Therapeutics (NASDAQ: TNGX) reported Q2 2024 financial results and business highlights. Key points include:
1. Ongoing dose expansion in TNG908 and TNG462 phase 1/2 clinical trials, with a comprehensive PRMT5 program update expected in 2H 2024.
2. TNG260 phase 1/2 clinical trial patient enrollment continues.
3. Strong cash position of $322.1 million as of June 30, 2024, with runway into 2027.
4. Q2 2024 financial results: Collaboration revenue $7.8 million, license revenue $12.1 million, R&D expenses $38.7 million, G&A expenses $10.8 million, net loss $25.6 million ($0.24 per share).
5. Gilead licensed a drug discovery program for a $12.0 million fee in June.
Tango Therapeutics (NASDAQ: TNGX), a clinical-stage biotech company specializing in precision cancer medicines, announced that CEO Barbara Weber, M.D., will present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 11, 2024, at 2:40 PM ET. The presentation will be webcast live on the company's website under the 'Events & Presentations' tab on the 'Investors' page, and a replay will be available for 90 days post-event.
Medivir announced that its licensee, Tango Therapeutics, has discontinued the clinical development of TNG348, a USP1 inhibitor aimed at treating BRCA1/2-mutant and HRD+ cancers, due to toxicity observed in phase 1/2 trials. The program was initially licensed from Medivir in 2020. Despite this setback, Medivir emphasized it remains focused on its lead program, fostroxacitabine bralpamide (fostrox), targeting primary liver cancer. The company is accelerating activities to initiate a pivotal phase 2b study for fostrox, which has the potential to secure market approval for treating HCC patients who fail current first-line treatments, a market projected to be worth $2.5 billion annually by 2028.
FAQ
What is the current stock price of Tango Therapeutics (TNGX)?
What is the market cap of Tango Therapeutics (TNGX)?
